CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 32 enrolled
Drug / intervention
CentriMag Ventricular Assist Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00819793
NCT00819793N/ACompleted
CompareCT.gov

Thoratec CentriMag VAS Failure-to-Wean From Cardiopulmonary Bypass Trial

Abbott Medical Devices·interventional·Posted Jan 9, 2009·Updated Jun 27, 2022

In Brief

A clinical study evaluating CentriMag Ventricular Assist System for Heart Failure. Completed, enrolled 32 participants across 14 sites.

Detailed Summary

The purpose of the study is to evaluate the safety and effectiveness of the CentriMag ventricular assist system to help patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsThoratec Corporation

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 9, 2009
Enrollment StartOct 1, 2008
Primary CompletionMay 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 17.5 years ago

Interventions

CentriMag Ventricular Assist Systemdevice

All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.